Deep Track Capital LP bought a new position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Rating) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 5,641,668 shares of the biopharmaceutical company’s stock, valued at approximately $28,208,000. Esperion Therapeutics comprises about 2.0% of Deep Track Capital LP’s portfolio, making the stock its 19th biggest holding. Deep Track Capital LP owned 19.40% of Esperion Therapeutics at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also bought and sold shares of ESPR. ProShare Advisors LLC bought a new stake in Esperion Therapeutics during the 4th quarter worth approximately $50,000. Spire Wealth Management bought a new stake in Esperion Therapeutics during the 4th quarter worth approximately $51,000. National Bank of Canada FI bought a new stake in Esperion Therapeutics during the 4th quarter worth approximately $61,000. Citigroup Inc. grew its holdings in Esperion Therapeutics by 187.9% during the 4th quarter. Citigroup Inc. now owns 14,641 shares of the biopharmaceutical company’s stock worth $73,000 after acquiring an additional 9,556 shares during the last quarter. Finally, Royal Bank of Canada grew its holdings in Esperion Therapeutics by 70.1% during the 2nd quarter. Royal Bank of Canada now owns 6,550 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 2,699 shares during the last quarter.
Shares of Esperion Therapeutics stock traded down $0.12 during trading on Thursday, reaching $5.51. 717,563 shares of the company traded hands, compared to its average volume of 1,336,856. Esperion Therapeutics, Inc. has a 1-year low of $3.28 and a 1-year high of $26.77. The company has a 50 day moving average price of $5.48 and a 200-day moving average price of $5.30. The firm has a market capitalization of $347.17 million, a PE ratio of -0.79 and a beta of 0.43.
ESPR has been the topic of a number of research reports. JPMorgan Chase & Co. raised shares of Esperion Therapeutics from an “underweight” rating to a “neutral” rating and set a $6.00 target price on the stock in a report on Wednesday, May 4th. StockNews.com started coverage on shares of Esperion Therapeutics in a research report on Thursday, March 31st. They issued a “sell” rating on the stock. Finally, HC Wainwright started coverage on shares of Esperion Therapeutics in a research report on Thursday, March 10th. They issued a “buy” rating and a $22.00 price target on the stock. Three research analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $21.11.
About Esperion Therapeutics (Get Rating)
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
- Get a free copy of the StockNews.com research report on Esperion Therapeutics (ESPR)
- Genesco Pops On Earnings But Don’t Expect A Rally
- The Insiders Are Selling Movado Group, But You Shouldn’t
- Beware The Rebound In Retail Stocks
- It’s A Good Time To Own Ralph Lauren (NYSE: RL)
- Block, Inc: Correcting for Negative Earnings
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.